Content overview: “FDA-Approved Flow Neuroscience Headset Offers New Depression Treatment Option in US Market”. The Flow Neuroscience headset, now available in the United States, has received FDA clearance as a non-invasive treatment for major depressive disorder. Developed by Flow Neuroscience, the device uses transcranial direct current stimulation (tDCS) to deliver targeted electrical impulses to brain regions linked to mood regulation. Clinical trials showed significant improvement in symptoms for many users, with some able to reduce or discontinue antidepressant medications under medical supervision.
The headset is designed for home use, requiring just 20-minute sessions five times a week over four weeks. Despite its $2,200 price tag—currently not covered by most insurance plans—the device represents a promising alternative for patients seeking drug-free mental health solutions. The approval marks a pivotal moment in digital therapeutics, positioning Flow Neuroscience at the forefront of neuromodulation technology. For the complete material, the listing points back to the source inside the network.